title: [New anticoagulants in the prevention and treatment of venous thromboembolism].
abstract: Clinical data on the risk factors, incidence, consequences and current treatment options of venous thromboembolism are reviewed. Current guidelines advise anticoagulant treatment for a few weeks or months in immobilized patients treated in hospital, and after major surgery. The initial treatment is based on heparin, followed by vitamin K antagonist treatment. Recently a number of new, partially orally administered medications have undergone clinical investigations and based on the results three of them were also registered for the prevention and treatment of venous thromboembolism. Direct thrombin inhibitors, direct and indirect Factor Xa inhibitors exhibited proven non-inferiority or superiority compared with traditional treatment options. The superior efficacy or non-inferiority was not accompanied with an increase in the bleeding risk. Results of the most important clinical trials are reviewed. Based on these results, prevention and treatment of venous thromboembolism will change substantially in the near future.
authors.affiliation: Gottsegen György Országos Kardiológiai Intézet, Budapest. keltai@kardio.hu
authors.forename: Mátyás
authors.initials: M
authors.lastname: Keltai
authors.forename: Katalin
authors.initials: K
authors.lastname: Keltai
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D000991:Antithrombins / Q000627:therapeutic use; D001562:Benzimidazoles / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D000069604:Dabigatran; D016527:Drug Costs; D015507:Drugs, Investigational / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D065427:Factor Xa Inhibitors; D006801:Humans; D006814:Hungary; D009025:Morpholines / Q000627:therapeutic use; D009844:Oligosaccharides / Q000627:therapeutic use; D011655:Pulmonary Embolism / Q000188:drug therapy* / Q000517:prevention & control*; D011720:Pyrazoles / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D011728:Pyridones / Q000627:therapeutic use; D000069552:Rivaroxaban; D013844:Thiazoles / Q000627:therapeutic use; D013876:Thiophenes / Q000627:therapeutic use; D013917:Thrombin / Q000037:antagonists & inhibitors; D054556:Venous Thromboembolism / Q000188:drug therapy* / Q000517:prevention & control*; D015091:beta-Alanine / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D000991:Antithrombins; D001562:Benzimidazoles; D015507:Drugs, Investigational; D065427:Factor Xa Inhibitors; D009025:Morpholines; D009844:Oligosaccharides; D011720:Pyrazoles; D011725:Pyridines; D011728:Pyridones; D013844:Thiazoles; D013876:Thiophenes; D015091:beta-Alanine; C522181:apixaban; C479958:idraparinux; D000069552:Rivaroxaban; D013917:Thrombin; D000069604:Dabigatran; C552171:edoxaban